Journal of Cancer Research and Immuno-Oncology
Open Access
ISSN: 2684-1266
+44-77-2385-9429
ISSN: 2684-1266
+44-77-2385-9429
Saryia Javed
NHS Greater Glasgow and Clyde Board HQ, United Kingdom
Scientific Tracks Abstracts: J Cancer Res Immunooncol
Globally, colorectal cancer (CRC) is one of the most typical lethal cancers. One of the main factors for better outcomes in CRC management is the early detection of the disease. As an integral component of human metabolism and homeostasis, gut microbiome has recently been a subject of extensive research for its role in the pathogenesis, diagnosis, and treatment of CRC. Microbial symbiosis (the decrease in beneficial gut flora and the increase of detrimental populations) leads to chronic inflammation and genetic alteration in the host cells, triggering and promoting CRC carcinogenesis. Identifying these microbial changes in depth would potentially isolate the pathogenic microbiota species and establish biomarker models for early detection of CRC. On the other hand, modifying these microbial changes would help formulate preventative and therapeutic strategies for CRC, developing a more precise CRC management plan according to each patient's microbial print. This essay explains gut microbiome composition, microbial changes (symbiosis) in CRC carcinogenesis, the probability of creating microbiomebased CRC biomarkers, and potential microbiome-targeted treatment options.
Dr.Saryia Javed has her expertise in evaluation and passion for improving health and wellbeing. Her open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. She has built this model after years of experience in research, evaluation, teaching and administration both in hospital and education institution .